Single and Multiple Dose Study of MK-1167 in Healthy Japanese Participants

A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1167 in Healthy Japanese Participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230399

Enrollment

Registered

2023-10-16

Start date

2023-10-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia Alzheimer's type

Interventions

In Part 1, a single oral dose of MK-1167 3, 12 or 25 mg, or placebo will be administered. In Part 2, multiple oral doses of MK-1167 or placebo will be administered at the dose level of 22 mg on Days 1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy Japanese males or postmenopausal females aged 18 to 45 years old

Exclusion criteria

Exclusion criteria: Has a history of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Pharmacokinetics (Evaluation of plasma pharmacokinetics, comparison of plasma pharmacokinetics among CYP2C19 phenotypes)	—

Contacts

Public ContactMSDJRCT inquiry mailbox

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026